Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China.
Lung Cancer Diagnosis and Treatment Center of Dalian, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China.
Cancer Biomark. 2018;22(2):301-310. doi: 10.3233/CBM-171017.
Patients with small (⩽ 2 cm) invasive lung adenocarcinoma are at high risk of poor prognosis and disease recurrence after complete surgical resection. Therefore, identification of high-risk individuals from these patients emerges as an urgent problem. Elevated MACC1 expression predicts a poor prognosis in multiple types of cancer that are independent of TNM staging. This study investigated the prognostic value of MACC1 expression in patients with small invasive lung adenocarcinoma.
The current study aimed to evaluate the relationship between MACC1 expression in patients' tumor tissue and prognosis in small invasive lung adenocarcinoma.
The records of 131 patients with small invasive lung adenocarcinoma who underwent complete surgical resection were reviewed. The MACC1 expression was detected by immunohistochemical staining in all specimens. Meanwhile, western blot and real-time quantitative PCR were used to examine the expression level of MACC1 in human lung adenocarcinoma cell lines. The effect of clinicopathological risk factors on patients' survival was analyzed using the Kaplan-Meier approach and multivariable Cox models.
Elevated MACC1 expression was observed in 53 (40.5%) specimens, and in A549, H358, H460 and H322 lung adenocarcinoma cell lines. MACC1 overexpression was associated with differentiation (P= 0.005) and blood vessel invasion (P= 0.001). Compared with low MACC1 expression, elevated MACC1 expression was associated with significantly shorter overall survival (odds ratio = 6.515; 95% confidence interval: 1.382-30.721; P= 0.018) and disease-free survival (odds ratio = 3.270; 95% confidence interval: 1.117-9.569; P= 0.031). Multivariate analyses demonstrated high MACC1 expression is an independent risk factor of worse overall survival (odds ratio = 5.684; 95% confidence interval: 1.145-28.210; P= 0.034) and disease-free survival (odds ratio = 4.667; 95% confidence interval: 1.372-15.877; P= 0.014).
MACC1 is an independent prognostic marker in patients with small invasive lung adenocarcinoma after complete surgical resection. Differential outcomes are associated with MACC1 expression level.
对于完全手术切除后的小（≤2cm）浸润性肺腺癌患者，其预后不良和疾病复发的风险较高。因此，从这些患者中识别高危个体成为当务之急。MACC1 表达升高预示着多种癌症的预后不良，且独立于 TNM 分期。本研究旨在探讨 MACC1 表达在小侵袭性肺腺癌患者中的预后价值。
本研究旨在评估患者肿瘤组织中 MACC1 表达与小侵袭性肺腺癌患者预后之间的关系。
回顾性分析 131 例接受完全手术切除的小侵袭性肺腺癌患者的临床资料。采用免疫组织化学染色检测所有标本的 MACC1 表达。同时，采用 Western blot 和实时定量 PCR 检测人肺腺癌细胞系中 MACC1 的表达水平。采用 Kaplan-Meier 法和多变量 Cox 模型分析临床病理危险因素对患者生存的影响。
在 53 例（40.5%）标本中观察到 MACC1 表达升高，在 A549、H358、H460 和 H322 肺腺癌细胞系中观察到 MACC1 过表达。MACC1 过表达与分化（P=0.005）和血管侵犯（P=0.001）相关。与低 MACC1 表达相比，高 MACC1 表达与总生存期明显缩短显著相关（比值比=6.515；95%置信区间：1.382-30.721；P=0.018）和无病生存期（比值比=3.270；95%置信区间：1.117-9.569；P=0.031）。多因素分析表明，高 MACC1 表达是总生存期较差的独立危险因素（比值比=5.684；95%置信区间：1.145-28.210；P=0.034）和无病生存期（比值比=4.667；95%置信区间：1.372-15.877；P=0.014）。
MACC1 是完全手术切除后的小侵袭性肺腺癌患者的独立预后标志物。不同的预后与 MACC1 表达水平相关。
